Industry Update: The latest developments in therapeutic delivery | Zendy

Louise Rosenmayr-Templeton | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Industry Update: The latest developments in therapeutic delivery

Author(s) -

Louise Rosenmayr-Templeton

Publication year - 2013

Publication title -

therapeutic delivery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.619

H-Index - 46

eISSN - 2041-6008

pISSN - 2041-5990

DOI - 10.4155/tde.13.15

Subject(s) - business , nanotechnology , materials science

This article covers the period 1–31 January 2013. During this timeframe Allergan agreed to take over MAP Pharmaceuticals, the US FDA granted marketing approval to an antisense oligonucleotide (mipomersen sodium) for the very first time, and Celgene released clinical data showing that Abraxane ® (paclitaxel protein-bound particles for injectable suspension) in combination with gemcitabine improved the overall survival of treatment-naive patients with metastatic pancreatic cancer. As ever, the article is largely based on information from press releases and company websites.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research